Ipsen to acquire Kartos; Enhertu’s Tumor-Agnostic EU Approval

Ipsen to acquire Kartos; Enhertu’s Tumor-Agnostic EU Approval

BioSeeker Group BioSeeker Group

BioSeeker Group

Award winning provider of the cancer drug intelligence solution 1stOncology

Published Jul 10, 2026
+ Follow
Article content

Agreement / Collaboration / M&A

Ipsen to acquire Kartos Therapeutics, expanding hemato-oncology late-stage pipeline

Excalipoint Therapeutics Announces Clinical Trial Collaboration with Roche to Evaluate EXP011 in DLL3‑Expressing Solid Tumors

Natera and Aveta Biomics Announce Strategic Partnership Supporting Global Phase 3 Registrational Trial of APG-157 in Head and Neck Cancer

Aptose Biosciences Announces Completion of Acquisition by Hanmi Pharmaceutical

Ratio Therapeutics Enters Strategic Actinium-225 Supply Agreement with PanTera to Support Radiopharmaceutical Development Programs

Vect-Horus announces collaboration and license option agreement with Servier to develop targeted oligonucleotide therapeutics for rare CNS diseases

Innovent Biologics and Lilly Enter into Commercialization Agreement for Verzenios® (abemaciclib) in Mainland China

Liminatus Pharma Amends Definitive Merger Agreement with InnocsAI to Expand Oncology Cell Therapy Pipeline

Orion Pharma announces agreement with Shilpa Medicare for nivolumab biosimilar for European market

METiS TechBio and Boulevard Bio Enter Global License Agreement for Trispecific T-cell Engager

Cumberland Pharmaceuticals Closes Strategic Transaction with Apotex

Valerio Therapeutics announces binding offer for the proposed acquisition of etherna immunotherapies, creating a global leader in targeted RNA medicines

Insilico Medicine Announces Collaboration with Takeda to Advance Strategic AI Drug Discovery

Abbisko Therapeutics and AstraZeneca Enter a Strategic Collaboration to Conduct the Clinical Trial of Lumipodlin (ABSK043), a First-in-Class Oral PD-L1 Inhibitor, in Combination with TAGRISSO® for NSCLC

ProBio's AAV Manufacturing Excellence Powers UC Irvine and GlyTR Therapeutics First‑in‑Class pan-cancer CAR‑T Program

Inocras and AimedBio Partner to Advance Cancer Drug Discovery and Precision Oncology with Whole Genome Intelligence

VERAXA Biotech Initiates Cell Line Development with ATUM to Advance its Lead BiTAC®-TCE Program

Sanyou Bio and Baiyunshan Xihe Join Forces to Advance Innovative Radiopharmaceuticals and Radiodiagnostics

Funding

Akari Therapeutics Completes Previously Announced PIPE, Strengthening Balance Sheet Ahead of Potential Key Clinical and Regulatory Milestones

Nuvectis Pharma Announces Pricing of $100 Million Public Offering of Common Stock

Aptevo Secures $1.5 Million Non-Dilutive Research Grant From the Andy Hill Care Fund to Advance APVO451, a Nectin-4-Targeted Trispecific Immunotherapy for Solid Tumors

Pyxis Oncology Announces Up to $114 Million Private Placement Financing to Advance MICVO Through Key Clinical Milestones

Flare Therapeutics Secures $85M in Insider-Led Series C Financing and Appoints Anna Protopapas as Chief Executive Officer

Zelluna ASA awarded NOK 16 million Research Council of Norway grant

AB Science announces today the successful completion of a capital increase of a total gross amount of EUR 2.3 million subscribed by a limited number of investors

BridgeBio Raises $1 Billion in Preferred Equity to Accelerate Present and Upcoming Launches

ORYZON Raises €12 Million and Signs a Financing Agreement with COFIDES to Strengthen its Balance Sheet and Accelerate its Clinical Programs

Alvotech further strengthens liquidity by securing term loan facility of $75 million

Recommended by LinkedIn

The $1.7B Question: What Takeda's AI Partnership Signals for Oncology Clinical Trial Operations
The $1.7B Question: What Takeda's AI Partnership…
Leila Cupersmith 5 months ago
Redefining Oncology Through Patient-Centric Biologics
Redefining Oncology Through Patient-Centric Biologics
Databridge Market Research 5 months ago
Insilico Medicine Announces US$888 Million Multi-Year Collaboration with Servier for Drug Discovery and Development in Oncology
Insilico Medicine Announces US$888 Million Multi-Year…
Insilico Medicine 6 months ago

Elicio Therapeutics Announces Pricing of $15 Million Registered Direct Offering

Submission / Acceptance / Opinion / Approval

Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors

Nuvation Bio Announces Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated in the United Kingdom

Orca Bio’s TREGZI™ Receives U.S. FDA Approval as First and Only Precision-Engineered Cell Therapy for Allogeneic Transplant in Adults with Hematological Malignancies

Novocure’s Optune Pax® Receives CE Mark for the Treatment of Locally Advanced Pancreatic Cancer

HUTCHMED Announces NMPA Approval for ORPATHYS® for the treatment of Gastric Cancer Patients with MET Amplification

Clinical Trial Results

Data on SAR-bisPSMA to be presented at EANM

AB Science reports completion of the step 3 of phase 1, evaluating the combination of AB8939 with venetoclax for the treatment of refractory or relapsed AML

Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free Survival

Imugene Reports First Complete Response in Concurrent BTKi Cohort of azer-cel Phase 1b Trial

AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)

New PROSPER Data Demonstrate Real-World Impact of Mogamulizumab on Symptoms and Health-Related Quality of Life in Mycosis Fungoides and Sézary Syndrome

ITM, Helmholtz Munich and the University of Münster Announce Updated Preliminary Phase 1 Data with ITM-31 in Glioblastoma Patients

Moleculin Reports Positive Phase 2/3 MIRACLE Interim Results, With Annamycin Complete Remission Rates 3-fold Greater than Control

Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-Term Safety and Tolerability, and Durable Clinical Activity in MEK/BRAF-Pretreated Patients, plus Protocol Expansion

BeOne Medicines Announces Positive Phase 3 Results for BRUKINSA in Frontline Mantle Cell Lymphoma

Imugene Reports Additional Complete Response in Concurrent BTKi Cohort of azer-cel Phase 1b Trial

Can-Fite Phase 2a Pancreatic Cancer Study with Namodenoson Achieves Primary Safety Endpoint and Demonstrates Durable Survival Outcomes in Advanced Disease

Intensity Therapeutics Provides Mid-Year Update Highlighting Late-Stage Development Programs and Strategic Partnering Opportunities for INT230-6

New Research Published in Nature Links Clinical Activity with HIF‑2a Biology in Advanced Kidney Cancer Patients Treated with Casdatifan

FDA Alignment to Advance ProstACT Global Phase 3 Trial

Roche’s divarasib shows superiority in head-to-head phase III trial against approved KRAS G12C inhibitors in non-small cell lung cancer

Northwest Biotherapeutics Announces Scientific Presentation on Propensity Score Matching at the British Neuro-Oncology Society Annual Meeting

Partner Therapeutics Announces Publication of Results From the eNRGy Trial of Zenocutuzumab in Patients with NRG1+ Cholangiocarcinoma in Journal of Clinical Oncology (JCO)

Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026

Treos Bio Presents New Translational Data Showing PolyPEPI1018 Plus Anti-PD-L1 Immunotherapy Remodels the Tumor Immune Microenvironment in MSS Colorectal Cancer


1stOncologyWeekly: LinkedIn 1stOncologyWeekly: LinkedIn

1stOncologyWeekly: LinkedIn

254 followers

+ Subscribe

To view or add a comment, sign in

More articles by BioSeeker Group

See all articles

Others also viewed

Similar topics

Explore content categories